Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Deciphering Heterogeneity: The Good, The Bad and The Different

Four online seminars launched by the University of Arizona College of Pharmacy are aimed at helping health care decision-makers understand how heterogeneity, or individual treatment effects, impact patient health outcomes.

The seminars are particularly relevant given the growing interest in comparative effectiveness research (CER), which can be very useful in helping patients and their health care providers make informed decisions about their treatment options. The challenge, however, is in figuring out whether the information will apply to an individual patient who might respond differently to that treatment. That’s because most CER studies examine how an “average” patient will respond to a treatment, leaving some patients wondering about whether CER findings will apply to them.

To address these concerns, the seminars explain how to evaluate CER findings for heterogeneity, the implications of applying “average” effects to individual patients or groups, and how heterogeneity influences patient outcomes. The seminars are geared toward medical and pharmacy directors, pharmacy managers, clinical support pharmacists, and clinicians.

The presentations include:

The seminars were developed by the Comparative Effectiveness Research Group at the University of Arizona College of Pharmacy with funding from the National Pharmaceutical Council.

In addition to the four seminars, the University of Arizona College of Pharmacy CER Group website features other heterogeneity tools and resources. These materials include two downloadable checklists, one to assess heterogeneity within a study, and another to assess heterogeneity across different studies, along with links to related websites and videos.

Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Newsletter Volume

E.V.I.dently: April 2016

MessageValue Assessment Through a Broader, Patient-Focused LensNPC has developed “Guiding Practices for Patient-Centered Value Assessment” to help...
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
Newsletter Volume

E.V.I.dently January 2016

MessageThe Importance of Evidence, Value, Access and Innovation in 2016In his annual health care outlook, NPC President Dan Leonard explains why...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Press Release

Michael Ciarametaro Joins National Pharmaceutical Council as Director of Research

Washington, DC (July 31, 2014)—The National Pharmaceutical Council (NPC) today announced that Michael Ciarametaro has joined the health policy...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

CER and the Environment for Health Care Decision-Making

The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is continuing to shed light on the current environment...
Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Blog Post

ASCO’s Clinical Pathways Recommendations and Remaining Challenges

The American Society of Clinical Oncology (ASCO) today released its “policy statement on clinical pathways in oncology,” which acknowledges the...
Blog Post

Key Considerations for Cost Effectiveness Thresholds

While putting a price tag on the value of health care services and the life years gained is common in countries including the United Kingdom, Canada...
Blog Post

CER Tweets of the Week: JCER Editorial on Treatment Sequences in Oncology; JNCCN Discusses CER Database Analyses (December 14-18, 2015)

What were comparative effectiveness research (CER) stakeholders talking about on Twitter this week? Popular topics included the Journal of...
cersurvey16

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the...

Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue

A study published in the September 2015 issue of The American Journal of Managed Care introduces a...
  •  
  • 1 of 16
  • >